Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (45 ops.)
Latest filing published 17 Feb 2026 for Enliven Therapeutics, Inc..
Filing timeline
BuySaleAnish Patel
Insider track record
Disclosed buys
0
Disclosed sells
45
Signal history
Anish Patel: trading record in brief
Anish Patel discloses dealings in Enliven Therapeutics, Inc. to SEC (Form 4). In total, 56 filings cover trades dated from 23 February 2023 to 12 February 2026.
Every open-market trade on record is a sale: 45 sales worth €5.3M. Besides market trades, the filings include 3 share grants and 8 option exercises. Since January 2026: no purchases and 2 sales on the market.
Most recently, on 17 February 2026, the filings show a share grant in Enliven Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Anish Patel
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations28 total
20,000 shares0Common StockSEC:0001967163-26-000002:0
48,057 shares@ US$27.984236.8% of flowCommon StockSEC:0001967163-26-000001:0
4,958 shares@ US$20.76222.8% of flowCommon StockSEC:0001967163-25-000005:0
6,054 shares@ US$17.35032.9% of flowCommon StockSEC:0001967163-25-000004:0
6,667 shares@ US$20.09793.7% of flowCommon StockSEC:0001967163-25-000003:0
6,667 shares@ US$20.24263.7% of flowCommon StockSEC:0001415889-25-024196:0
6,262 shares@ US$18.19693.1% of flowCommon StockSEC:0001415889-25-021456:0
6,362 shares@ US$19.74833.4% of flowCommon StockSEC:0001415889-25-019609:0
6,607 shares@ US$20.32763.8% of flowCommon StockSEC:0001415889-25-016734:0
6,173 shares@ US$18.29693.2% of flowCommon StockSEC:0001415889-25-012591:0
3,756 shares@ US$17.80872.0% of flowCommon StockSEC:0001415889-25-010474:0
6,667 shares@ US$21.43944.2% of flowCommon StockSEC:0001415889-25-007683:0
6,667 shares@ US$21.92984.5% of flowCommon StockSEC:0001415889-25-003515:0
10,700 shares@ US$1.120.4% of flowCommon StockSEC:0001415889-25-001301:0
716 shares@ US$30.00350.6% of flowCommon StockSEC:0001415889-24-025505:0
17,475 shares@ US$25.069812.9% of flowCommon StockSEC:0001415889-24-019600:0
1,133 shares@ US$2.480.1% of flowCommon StockSEC:0001415889-24-016279:0
1,107 shares@ US$2.480.1% of flowCommon StockSEC:0001415889-24-013383:0
260 shares@ US$2.480.0% of flowCommon StockSEC:0001415889-24-013071:0
4,875 shares@ US$2.480.4% of flowCommon StockSEC:0001415889-24-012652:0
14,903 shares@ US$2.481.1% of flowCommon StockSEC:0001415889-24-010831:0
4,331 shares@ US$18.50252.4% of flowCommon StockSEC:0001415889-24-010676:0
4,875 shares@ US$15.63872.2% of flowCommon StockSEC:0001415889-24-007457:0
4,875 shares@ US$15.10942.2% of flowCommon StockSEC:0001415889-24-003122:0
4,875 shares@ US$15.1352.2% of flowCommon StockSEC:0001209191-24-002190:0
25 of 28 declarations
